Risk Factor For Nephrolithiasis Research Articles

The Prevalence of Nephrolithiasis and Associated Risk Factors Among the Population of the Riyadh Province, Saudi Arabia.

Background and objective Kidney stones, also referred to as nephrolithiasis or renal calculi, is a condition where crystal depositions are formed within the kidney and ideally excreted from the body via the urethra with no pain; however, larger calculi may cause significant pain and require further medical assistance. The vast majority of patients who develop renal calculi form calcium stones, which are either a composition of calcium oxalate or calcium phosphate. Other types include uric acid, struvite, and cysteine. While kidney stones are one of the most significant diseases among the Saudi population, which require an acute emergency intervention to prevent serious long-term complications,there are limited studies published regarding this condition inSaudi communities. In light of this, we performed this study to assess the prevalence, incidence, and risk factors of kidney stones among the population of Riyadh, Saudi Arabia. Methods This was a cross-sectional studyconducted in Riyadh, Saudi Arabia between Augustand October 2023, aiming to estimate the prevalence and risk factors of nephrolithiasis among residents of the Riyadh province. Data were collected through an electronic questionnairein both Arabic and Englishand distributed via social media in addition to barcode handouts in various selected venues in Riyadh. The questionnaire involved 12 questions categorized into three sections. The first section obtained demographical information while the second sectioncollected data about the past medical history of the participants. Lastly, the third section aimedto assess the prevalence of nephrolithiasis among participants or any history of the condition among their families. Results Atotal of 1,043 participants were surveyed, of whom 533 were males (51.1%). The prevalence of kidney stones was reported in 98 individuals (9.4%) overall. Individuals in the age groups of 36-50, 51-60, and >60 years showed significantly more renal stone prevalence than those in younger age groups (p<0.001). The prevalencewas found to be higher in participants who were smokers, diabetic, hypertensive, and those who suffered from inflammatory bowel disease (IBD), gout, chronic kidney disease (CKD), hyperthyroidism, and hyperparathyroidism. Participants who took calcium supplements or had a positive family history of renal stones were found to have a higher prevalence of renal stones as well. However, only hypertension, gout, and family history showed any statistical significance (p<0.05). Conclusions A direct correlation was observed between hypertension, gout, positive family history, and aging and an increased prevalence of kidney stones among theinhabitants of the Riyadh province. Therefore, we encourage the local authorities to raise awareness of kidney stones and their related risk factors among the general public. Moreover, further local studies need to be conducted to gain deeper insights into kidney stone prevalence, especially pertaining to associated comorbiditiesand the pattern of the disease itself.

Assessment of risk factors for nephrolithiasis in Rawat.

Objective: To identify the risk factors for nephrolithiasis among all patients found to have nephrolithiasis on renal sonography. The study will help us report the incidence of renal stones in this area, and as they cause significant morbidity and high costs of healthcare, and guide towards the introduction of public health measures to reduce the incidence of nephrolithiasis. Study Design: Descriptive, Questionnaire Based Cross-sectional study. Setting: Watim General Hospital, Rawalpindi. Period: Jul 1st, 2023 to Sep 30th, 2023. Material &amp; Methods: The data of all adult patients who underwent renal sonography and were documented to have nephrolithiasis was obtained through physician administered questionnaires from the ultrasound department records. Data was then entered and analyzed by using the Statistical Package for the Social Sciences (SPSS), version 16. Results: Data was collected on 115 patients, of these, 57% were males. 48% of the patients were aged between 18-30 years of age. 54% of the patients belonged to lower socio-economic class. 55% of them had low water intake, and 81% consumed non-purified water. 51% patients also had a positive family history. 81% of the patients had less intake of citrus fruits and 37% of them never exercised. Conclusion: Many significant risk factors were assessed. Awareness campaigns and preventive health measures should be implemented addressing the critical risk factors. This will help decrease the burden on patients, and on the health care system.

Management of nephrolithiasis in the Middle East over a recent decade: A systematic review.

Nephrolithiasis is a prevalent issue around the globe, particularly in hot climates such as Saudi Arabia. This analysis's objectives were to investigate the characteristics of kidney stones in Eastern Saudi Arabia and to provide the following findings: urinary stone composition, gender and age distribution, seasonal variations in stone formation, coexisting diseases linked to stone development, and urinary stone incidence. With comparisons to European and American populations, the primary risk factors for nephrolithiasis in Asian populations are to be determined through this systematic review and meta-analysis. We synthesized data from 13 geographically different studies using a thorough literature search through PubMed, ScienceDirect, and ResearchGate following the Preferred Reporting Items of Systematic Reviews and Meta-Analyses criteria. Potential targets for specialized public health programs were highlighted by the elucidation of differences in health-care-seeking behavior and disparities in health-care access. The results of this systematic analysis give doctors, researchers, and policymakers a thorough understanding of the condition of nephrolithiasis care in Saudi Arabia today. In addition, to maximize the care of nephrolithiasis in this particular group, this review identifies information gaps and highlights the necessity of context-specific guidelines and future research initiatives. All things considered, this systematic review addresses the unique possibilities and problems that exist within the Saudi Arabian health-care sector while also adding to the worldwide conversation on nephrolithiasis.

Assessment of metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease: a cross-sectional study.

Nephrolithiasis is more common in autosomal dominant polycystic kidney disease (ADPKD) than in the normal population. We aimed to investigate the anatomical and metabolic factors that may be associated with nephrolithiasis in patients with ADPKD METHODS: In this cross-sectional study, a total of 180 participants were included. Eighty-five patients with ADPKD [42 patients with nephrolithiasis (PKD N +) and 43 without nephrolithiasis (PKD N -)] were recruited. Forty-seven nephrolithiasis patients without ADPKD (N) and 48 healthy controls (HC) were selected as control groups. 24-h urine collections were measured in all participants. 24-h urine citrate, calcium, urate, oxalate, magnesium and sodium, serum electrolytes, and eGFRs were compared. Total kidney volumes were not different between patients with PKD N + and PKD N -. Hypocitraturia was common in all patients with ADPKD (69.4%), and it was not different between PKD N + (76.2%) and PKD N- (62.8%). However, hypocitraturia was statistically higher in PKD N + and PKD N - than in N (38.3%) and HC (12.5%) (p<0.05). 24-h urine calcium, urate, and oxalate levels were similar between PKD N + and PKD N - CONCLUSIONS: Hypocitraturia was found to be significantly higher in patients with ADPKD than in healthy adults and other kidney stone patients.

Low Potassium Intake: A Common Risk Factor for Nephrolithiasis in Patients with High Blood Pressure.

Hypertension (Htn) is a crucial cause of cardio-vascular and chronic kidney disease. Moreover, it is an independent risk factor for nephrolithiasis (NL). A diet rich in vegetables and fruits is indicated for both Htn and NL prevention, and the 24-h urinary potassium excretion can be used as a warning light for adherence. The aim of this study is to demonstrate the association between urinary potassium excretion and recurrent nephrolithiasis among patients affected by Htn. We have analyzed medical records of 119 patients affected by Htn and NL (SF-Hs) referring to Bone and Mineral Metabolism laboratory and 119 patients affected by Htn but without NL (nSF-Hs) referring to Hypertension and Organ Damage Hypertension related laboratory, both in Federico II University of Naples. The potassium 24-h urinary levels in SF-Hs were significantly lower compared to nSF-Hs. This difference was confirmed by the multivariable linear regression analysis in the unadjusted model and adjusted model for age, gender, metabolic syndrome, and body mass index. In conclusion, a higher potassium urinary excretion in 24-h is a protective factor against NL in patients affected by Htn and dietary interventions can be considered for kidney protection.

MP10-05 LITHOPROTECTIVE EFFECT OF GLP-1 AGONISTS IN DIABETIC STONE FORMERS

You have accessJournal of UrologyCME1 Apr 2023MP10-05 LITHOPROTECTIVE EFFECT OF GLP-1 AGONISTS IN DIABETIC STONE FORMERS Kelley Zhao, Brian Shkolnik, Jennifer Lu, Joshua Miller, and David Schulsinger Kelley ZhaoKelley Zhao More articles by this author , Brian ShkolnikBrian Shkolnik More articles by this author , Jennifer LuJennifer Lu More articles by this author , Joshua MillerJoshua Miller More articles by this author , and David SchulsingerDavid Schulsinger More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003225.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Type 2 Diabetes mellitus (T2DM) is associated with increased risk of calcium oxalate and uric acid (UA) stones. The most commonly prescribed medication for T2DM, Metformin, worsens this risk by increasing urinary oxalate, increasing urinary calcium and decreasing urine pH. With the increasing popularity of next-generation hypoglycemic agents, it is important to study the risk of stone formation with these newer medications. This study aims to assess the effects of various hypoglycemic agents on 24-hour urine studies in diabetic stone formers. METHODS: A retrospective review was conducted for all patients with a history of nephrolithiasis and a 24-hour urine study seen between July 2017-December 2019 for an outpatient visit. Patients with T2DM were assessed for use of hypoglycemic agents (metformin, sulfonylurea, GLP-1 agonist, DPP-4 inhibitors, SGLT-2 inhibitors, insulin), stone analysis, BMI, HbA1c, and 24-hour urine study. Two-tailed t-tests were used for mean comparison and chi square tests for stone rate comparison. RESULTS: Among the included 510 patients, 86 had T2DM (45 males, 41 females, mean age 63.6 years). Compared to the non-T2DM cohort, T2DM patients had lower urine pH (5.62 vs 6.14, p<0.00001), higher urine oxalate (41.7 vs 36.14, p=0.013) and higher UA supersaturation (1.45 vs 0.94, p<0.00001). Patients on GLP-1 agonists had greater urinary citrate than both the T2DM cohort (927.94 vs 544.59, p=0.007) and the non-T2DM cohort (566.55, p<0.0001). Between diabetic GLP-1 agonist users and non-users, there was no significant difference in BMI (non-GLP 33.1 vs GLP 35.4, p=0.34) or HbA1c (non-GLP 7.0 vs GLP 7.2, p=0.74). Though T2DM patients had higher rates of UA stones (31.7% vs 12.1%, p<0.0001), GLP-1 agonists users did not have a higher rate of UA stones compared to non-T2DM patients (18.2% vs 12.1%, p=0.54). There were no significant differences found with Metformin, sulfonylurea, DPP-4 inhibitors, SGLT-2 inhibitors, or insulin. CONCLUSIONS: T2DM is a known risk factor for nephrolithiasis, however, treatment with GLP-1 agonists may be litho-protective. The significant increase in urine citrate and reduction in UA stone formation suggests a lithoprotective effect of GLP-1 agonists independent of weight or diabetes control. Consideration should be made to recommend GLP-1 agonists to T2DM patients with nephrolithiasis. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e115 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kelley Zhao More articles by this author Brian Shkolnik More articles by this author Jennifer Lu More articles by this author Joshua Miller More articles by this author David Schulsinger More articles by this author Expand All Advertisement PDF downloadLoading ...

MP10-06 RISK FACTORS FOR NEPHROLITHIASIS IN 24-HOUR URINE STUDIES OF PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)

You have accessJournal of UrologyCME1 Apr 2023MP10-06 RISK FACTORS FOR NEPHROLITHIASIS IN 24-HOUR URINE STUDIES OF PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) Michelle Chen, Alex Nourian, Johnathan Drevik, Eric Ghiraldi, and Justin Friedlander Michelle ChenMichelle Chen More articles by this author , Alex NourianAlex Nourian More articles by this author , Johnathan DrevikJohnathan Drevik More articles by this author , Eric GhiraldiEric Ghiraldi More articles by this author , and Justin FriedlanderJustin Friedlander More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003225.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Nonalcoholic fatty liver disease (NAFLD) has been suggested to be an independent risk factor for renal stone disease by several studies. We aimed to identify abnormalities on 24-hour urine collection in this patient population. METHODS: 24-hour urine collections from a single tertiary care center were retrospectively reviewed from May 2014 to May 2021. Univariate analysis was performed using Chi-square test and unpaired T-test for categorical and continuous variables, respectively. A multivariable logistic regression was performed controlling for age, body mass index (BMI), diabetes mellitus (DM). RESULTS: 98 (24%) of 406 patients who met inclusion criteria were identified to have radiographic hepatic steatosis. There were no differences in baseline characteristics between groups including age, race, and gender. On univariate analysis, patients with NAFLD had decreased urinary pH (5.88 vs 6.06, p=0.02), elevated urinary oxalate (40 vs 36, p=0.04), calcium (219 vs 186, p=0.02) and sodium (185 vs 163, p=0.02) relative to those who did not have fatty infiltration of the liver on imaging. After controlling for DM and obesity as defined as BMI≥30, no 24-hour urine abnormalities were identified. CONCLUSIONS: After adjusting for confounding factors, patients with hepatic steatosis did not have identifiable abnormalities in their 24-hour urine studies. Increased risk of nephrolithiasis in patients with NAFLD is likely related to contributors of metabolic syndrome such as diabetes and obesity. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e116 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Michelle Chen More articles by this author Alex Nourian More articles by this author Johnathan Drevik More articles by this author Eric Ghiraldi More articles by this author Justin Friedlander More articles by this author Expand All Advertisement PDF downloadLoading ...

Pancreatic exocrine insufficiency is a risk factor for kidney stones in patients with chronic pancreatitis

IntroductionMost patients with chronic pancreatitis (CP) develop pancreatic exocrine insufficiency (PEI) over the course of the disease. PEI may lead to hyperoxaluria and development of urinary oxalate stones. It has been postulated that the patients with CP may be at increased risk of kidney stone formation, but the data is scarce. We aimed to estimate incidence and risk factors for nephrolithiasis in a Swedish cohort of patients with CP. Patients and methodsWe performed retrospective analysis of an electronical medical database of patients diagnosed with definite CP during 2003–2020. We excluded patients <18 years of age, those with missing relevant data in medical charts, patients with probable CP (according to the M-ANNHEIM classification system) and those in whom kidney stones were diagnosed before CP diagnosis. ResultsSome 632 patients with definite CP were followed over a median of 5.3 (IQR 2.4–6.9) years. There were 41 (6.5%) patients diagnosed with kidney stones, of whom 33 (80.5%) were symptomatic. Comparing to patients without kidney stones, patients with nephrolithiasis were older, with median age of 65 (IQR 51–72) years, and a male predominance (80% vs 63%). Cumulative incidence of kidney stones was 2.1%, 5.7%, 12.4% and 16.1% at 5, 10, 15, and 20 years after CP diagnosis, respectively. Multivariable cause-specific Cox regression analysis revealed PEI as independent risk factor for nephrolithiasis (adjusted HR 4.95, 95%CI 1.65–14.84; p = 0.004). Another risk factors were increase in BMI (aHR 1.16 95% CI 1.04–1.30; p = 0.001 per unit increment), and a male sex (4.51, 95% CI 1.01–20.3, p = 0.049). ConclusionPEI and increase in BMI are risk factors for kidney stone development in patients with CP. Male CP patents are particularly at increased risk of nephrolithiasis. This should be taken into consideration in general clinical approach to raise awareness among patients and medical workers.

The ABCG2 rs2231142 polymorphism and the risk of nephrolithiasis: A case-control study from the Taiwan biobank.

Hyperuricemia and gout are risk factors of nephrolithiasis. However, it is unclear whether the ABCG2 gene contributes to the development of nephrolithiasis. We aimed to investigate the interaction between the ABCG2 rs2231142 variant and incident nephrolithiasis in the Taiwanese population. A total of 120,267 adults aged 30-70 years were enrolled from the Taiwan Biobank data-base in this retrospective case-control study and genotyped for rs2231142. The primary outcome was the prevalence of self-reported nephrolithiasis. The odds ratio (OR) of incident nephrolithiasis was analyzed by multivariable logistic regression models with adjustment for multifactorial confounding factors. Associations of the ABCG2 rs2231142 variant with serum uric acid levels, and the incident nephrolithiasis were explored. The frequency of rs2231142 T allele was 53%, and 8,410 participants had nephrolithiasis. The multivariable-adjusted OR (95% confidence interval) of nephrolithiasis was 1.18 (1.09-1.28) and 1.12 (1.06-1.18) for TT and GT genotypes, respectively, compared with the GG genotype (p<0.001), specifically in the male population with hyperuricemia. Higher age, male sex, hyperlipidemia, hypertension, diabetes mellitus, hyperuricemia, smoking and overweight were independent risk factors for nephrolithiasis. In contrast, regular physical exercise is a protective factor against nephrolithiasis. ABCG2 genetic variation is a significant risk of nephrolithiasis, independent of serum uric acid levels. For rs2231142 T allele carriers, our result provides evidence for precision healthcare to tackle hyperuricemia, comorbidities, smoking, and overweight, and recommend regular physical exercise for the prevention of nephrolithiasis.

PROPORTION OF TYPE 2 DIABETES AMONG PATIENTS WITH UPPER TRACT UROLITHIASIS

Introduction: All industrialized nations are currently witnessing a steep rise in the incidence of urinary stone diseases, which closely follow the trends of obesity, metabolic syndrome, and type 2 diabetes. Aims: To nd the proportion of Type 2 Diabetes among patients with upper tract urolithiasis. Material &amp; methods: The present study was a Cross-Sectional study. This Study was conducted from July 2021 to June 2022 at Department of Urology, Government Medical College, Thiruvananthapuram. Total 285 patients were included in this study. Result: In the serum prole of 285 patients, statistically signicant differences were found in the values of S. Creatinine (p&lt;0.001), S. Calcium (p=0.029) and Fasting Blood Sugar (p&lt;0.001). Urea (p=0.025) and uric acid (0.012) also showed statistically signicant differences in the two groups. Conclusion:In the current global scenario, obesity and type 2 diabetes are considered as epidemic. Both of them are considered as independent risk factors for nephrolithiasis

Unravelling the Complex Relationship between Diet and Nephrolithiasis: The Role of Nutrigenomics and Nutrigenetics.

Nephrolithiasis is an increasingly prevalent condition, especially in high income countries, and is associated with high morbidity. Extraordinary progress in genetics made the identification of genetic forms of nephrolithiasis possible. These genetic diseases are usually rare and do not account for the most common forms of nephrolithiasis that are the result of several factors such as environment, dietary habits, and predisposing genes. This knowledge has shaped what we classify as nephrolithiasis, a condition that is now recognized as systemic. How and to what extent all these factors interact with one another and end in kidney stone formation, growth, and recurrence is not completely understood. Two new research fields have recently been trying to give some answers: nutrigenomics and nutrigenetics. These fields have the aim of understanding the intricate diet/genome interface that influences gene expression regulation mainly through epigenetic mechanisms and results in specific medical conditions such as cancer, metabolic syndrome, and cardiovascular diseases. Epigenetics seems to play a crucial role and could represent the link between environmental factors, that we are constantly exposed to, and risk factors for nephrolithiasis. In this systematic review, we summarize all the available evidence of proven or hypothesized epigenetic mechanisms related to nephrolithiasis.

RF16 | PSUN155 Empagliflozin and the risk of nephrolithiasis

Abstract Aims Nephrolithiasis is a common disease, estimated to affect 10% of the US population. In addition to pain, often severe, it can lead to urinary tract infections and acute kidney injury, while contributing to health care costs from emergency room visits and follow-up interventions necessary to relieve stone burden. Type 2 diabetes (T2D) is a well-known risk factor for nephrolithiasis. Recently in an observational study of patients with T2D, use of sodium-glucose transport protein 2 (SGLT2) inhibitors as glucose lowering agents was associated with a 49% lower risk of nephrolithiasis when compared with use of glucagon like peptide 1 (GLP-1) receptor agonists. We examined, prospectively, the association between renal stone disease and the use of the SGLT2 inhibitor empagliflozin, using existing data from randomized clinical trials. Methods Pooled data from 15,081 patients with T2D treated with empagliflozin (10,177) or placebo (4,904) from 20 phase I-IV randomized, placebo-controlled trials including the large cardiovascular outcome trial, EMPA-REG OUTCOME, were included in this analysis. Incident urinary tract stone events were captured using a pre-defined collection of MedDRA terms: nephrolithiasis, renal colic, ureterolithiasis, calculus bladder, calculus urinary, calculus urethral, and nephrocalcinosis (MedDRA version 22.1). A sensitivity analysis used a narrower definition by excluding the terms renal colic and nephrocalcinosis. Incidence rate ratios (IRR) and 95% confidence intervals (CI) were calculated using the relative risk estimate stratified by study. Results The median exposure to study drug was 543 (placebo) and 549 (empagliflozin 10 or 25 mg) days We found that a total of 183 patients experienced an incident urolithiasis during follow-up (79 in placebo, 104 in pooled empagliflozin) yielding annual incidence rates of 1.01 versus 0.63 events per 100 patient years in placebo and empagliflozin, respectively. All but one event occurred in patients with no prior history of urinary tract stones. The IRR was 0.64 (95% CI 0.48, 0.86), in favor of empagliflozin. In the sensitivity analysis, now restricted to nephrolithiasis, ureterolithiasis, calculus bladder, calculus urinary, and calculus urethral, the results were similar (IRR, empagliflozin vs. placebo, 0.62 [95% CI 0.45, 0.85]). Conclusion As compared to placebo, use of empagliflozin was associated with an approximate 40% reduction in the risk of urolithiasis in patients with T2D. Alterations in lithogenic profile of the urine (including dilutional effects) of potential stone formers after SGLT2 inhibition may explain this finding. Based on these initial observations, mechanistic studies to elucidate the mediator(s) of this seemingly protective effect and dedicated randomized prospective clinical trials appear warranted in patients with renal stone disease. As with follow-up SGLT2 inhibitor investigations conducted in patients with heart failure and chronic kidney disease, such trials should include individuals who do not have T2D. Presentation: Sunday, June 12, 2022 12:30 p.m. - 2:30 p.m., Sunday, June 12, 2022 1:12 p.m. - 1:17 p.m.

Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?

Diabetes mellitus is a risk factor for nephrolithiasis. A recent observational study found that in patients with type 2 diabetes (T2D), SGLT2 inhibitor use was associated with a 49% lower risk of nephrolithiasis compared with GLP-1 receptor agonists.&#x0D; Aim: we examined the association between nephrolithiasis and the SGLT2 inhibitor empagliflozin, using existing data from randomized clinical trials.&#x0D; Methods: we pooled data from 15 081 T2D patients randomized to empagliflozin (n = 10 177) or placebo (n = 4904) from 20 phase I-IV trials, including the large cardiovascular outcome trial, EMPA-REG OUTCOME. Incident urinary tract stone events were captured using a predefined collection of MedRA terms. A sensitivity analysis using a narrower definition was also performed. Incidence rate ratios (IRR) and 95% CIs were calculated using the relative risk estimate, stratified by study.&#x0D; Results: the median exposures to study drug were 543 days (placebo) and 549 days (empagliflozin); 183 patients experienced an incident urolithiasis during follow-up (placebo, 79; empagliflozin, 104), yielding annual incidence rates of 1.01 vs 0.63 events/100 patient-years in the 2 respective groups. The IRR was 0.64 (95% CI, 0.48-0.86), in favor of empagliflozin. In the sensitivity analysis, the results were similar (IRR, 0.62 [95% CI, 0.45-0.85]).&#x0D; Conclusion: compared with placebo, empagliflozin therapy was associated with an approximate 40% reduced risk of urinary tract stone events in T2D patients. The underlying mechanisms are unknown but may involve altered lithogenic profile of the urine. Dedicated randomized prospective clinical trials are warranted to confirm these initial observations in patients with and without T2D.

Risk Factors of Nephrolithiasis in a Tertiary Care Hospital in Rawalpindi: A Descriptive Cross-Sectional Study.

BackgroundNephrolithiasis (renal stones) is the most common urological disease. Its prevalence is high in every part of the world. Several factors lead to renal stone formation. In Pakistan, nephrolithiasis prevalence is also high as Pakistan is located in a region which is known as the salt belt. However, nephrolithiasis and its possible risk factors are under-researched in Pakistan.ObjectiveThis study aims to identify the risk factors for nephrolithiasis among admitted patients with renal stones. This may lead to a reduction in renal stone incidence and its allied complications by the prevention of risk factors that would have a major role in renal stone formation.Material and methodsThis descriptive cross-sectional study was performed among the 143 admitted patients with renal stones in the urology ward of Benazir Bhutto Hospital, Rawalpindi, for approximately six months from November 2021 to April 2022. Non-probability convenient sampling and developed inclusion and exclusion criteria were used for the recruitment of patients. After elaborating on the objectives, the study data were collected by interviewers through a self-structured questionnaire. Descriptive analysis was carried out using SPSS version 25.0 (IBM Corp., Armonk, NY).ResultsNephrolithiasis was more prevalent among patients who had an age group range of 15-30 years (47.55%), male gender (56.65%), illiterate educational status (53.14%), lower socioeconomic status (66.43%), inadequate intake of water (61.53%), used tap water (56.64%), a habit of daily vegetable intake (65.04%), sedentary lifestyle (51.74%), family history of renal stones (57.34%), no diabetes mellitus (62.94%), no hypertension (52.45%), and overweight (48.23%).ConclusionIn brief, the age group of 15-30 years, male gender, illiteracy, lower socioeconomic status, insufficient water intake, tap water, high vegetables, inactive lifestyle, family history of nephrolithiasis, and a high BMI all increase the risk of nephrolithiasis.

Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?

ContextDiabetes mellitus is a risk factor for nephrolithiasis. A recent observational study found that in patients with type 2 diabetes (T2D), SGLT2 inhibitor use was associated with a 49% lower risk of nephrolithiasis compared with GLP-1 receptor agonists.ObjectiveWe examined the association between nephrolithiasis and the SGLT2 inhibitor empagliflozin, using existing data from randomized clinical trials.MethodsWe pooled data from 15 081 T2D patients randomized to empagliflozin (n = 10 177) or placebo (n = 4904) from 20 phase I-IV trials, including the large cardiovascular outcome trial, EMPA-REG OUTCOME. Incident urinary tract stone events were captured using a predefined collection of MedRA terms. A sensitivity analysis using a narrower definition was also performed. Incidence rate ratios (IRR) and 95% CIs were calculated using the relative risk estimate, stratified by study.ResultsThe median exposures to study drug were 543 days (placebo) and 549 days (empagliflozin); 183 patients experienced an incident urolithiasis during follow-up (placebo, 79; empagliflozin, 104), yielding annual incidence rates of 1.01 vs 0.63 events/100 patient-years in the 2 respective groups. The IRR was 0.64 (95% CI, 0.48-0.86), in favor of empagliflozin. In the sensitivity analysis, the results were similar (IRR, 0.62 [95% CI, 0.45-0.85]).ConclusionCompared with placebo, empagliflozin therapy was associated with an approximate 40% reduced risk of urinary tract stone events in T2D patients. The underlying mechanisms are unknown but may involve altered lithogenic profile of the urine. Dedicated randomized prospective clinical trials are warranted to confirm these initial observations in patients with and without T2D.

Conhecimento e atitudes de pacientes portadores de nefrolitíase: estudo transversal

Nephrolithiasis is a common urinary tract disease with an increasing prevalence, mainly due to the lack of control of modifiable risk factors. The aim of this study was to assess the level of knowledge about risk factors for nephrolithiasis and patients' attitudes. This is a cross-sectional, observational, descriptive, and analytical study based on a review of medical records and through an online survey of patients diagnosed with nephrolithiasis during follow-up at a private nephrology clinic in Joinville, Brazil. Gender, age, comorbidities, laboratory values, knowledge, and attitudes were evaluated. An explanatory multivariate model was proposed to assess the effect of knowledge and attitudes on risk factors for nephrolithiasis. Of the 129 participants, 44 (34%) were men, median age 42 years and median time to diagnosis 5 years. Hypertension was the most prevalent comorbidity in 26%. In 42% of patients, there was weight gain since the first consultation. Alone, excessive salt consumption (98%), low water intake (77%) and high protein consumption (67%) were the most identified risk factors. After adjusting for confounders, greater knowledge was not associated with weight gain (OR=0.94; 95% CI 0.73-1.22; p=0.661) or lower salt intake (OR=1.26; 95% CI 0.95-1.67; p=0.106). Greater knowledge was associated with greater daily fluid intake (OR=1.50; 95% CI 1.11-2.01; p=0.008). Although there is little knowledge of all nephrolithiasis risk factors, measures to increase awareness can contribute to preventive attitudes.

Knowledge and attitudes of patients with nephrolithiasis: a crosssectional study

Nephrolithiasis is a common urinary tract disease with an increasing prevalence, mainly due to the lack of control of modifiable risk factors. The aim of this study was to assess the level of knowledge about risk factors for nephrolithiasis and patients' attitudes. This is a cross-sectional, observational, descriptive, and analytical study based on a review of medical records and through an online survey of patients diagnosed with nephrolithiasis during follow-up at a private nephrology clinic in Joinville, Brazil. Gender, age, comorbidities, laboratory values, knowledge, and attitudes were evaluated. An explanatory multivariate model was proposed to assess the effect of knowledge and attitudes on risk factors for nephrolithiasis. Of the 129 participants, 44 (34%) were men, median age 42 years and median time to diagnosis 5 years. Hypertension was the most prevalent comorbidity in 26%. In 42% of patients, there was weight gain since the first consultation. Alone, excessive salt consumption (98%), low water intake (77%) and high protein consumption (67%) were the most identified risk factors. After adjusting for confounders, greater knowledge was not associated with weight gain (OR=0.94; 95% CI 0.73-1.22; p=0.661) or lower salt intake (OR=1.26; 95% CI 0.95-1.67; p=0.106). Greater knowledge was associated with greater daily fluid intake (OR=1.50; 95% CI 1.11-2.01; p=0.008). Although there is little knowledge of all nephrolithiasis risk factors, measures to increase awareness can contribute to preventive attitudes.

Kidney Stones in Transfusion-Dependent Thalassemia: Prevalence and Risk Factors

Purpose: As patients with transfusion-dependent thalassemia (TDT) are living longer, novel morbidities are being recognized. The purpose of this review is to summarize the current knowledge regarding the prevalence and risk factors of nephrolithiasis in patients with TDT. Methods: A non-systematic, narrative review of the current literature published up to August 2021 was conducted. Results: Nephrolithiasis has been reported in 18% - 59% of patients with TDT, which is at least twice the prevalence in the general US population. The risk factors for nephrolithiasis can be classified into behavioral (dietary and lifestyle), environmental, metabolic, disease-specific, and genetic factors. While clarifying the true prevalence of nephrolithiasis in different age groups and diagnostic categories of TDT requires further research, prevention, and management of nephrolithiasis is a growing clinical concern. Physicians should be aware of the potential increased risk of stone disease in splenectomized and diabetic patients as well as those treated with certain chelation regimens. Conclusions: The etiology of nephrolithiasis and potential TDT-specific risk factors that may put patients at greater risk are highlighted. There is insufficient evidence at this time to recommend universal screening for nephrolithiasis using ultrasound. Evidence-based recommendations on monitoring, prevention, and management of nephrolithiasis in TDT are provided.

Removal of Large Urinary Stone Using Percutaneous Nephrolithotomy in a Patient with Crohn’s Disease

&lt;p&gt;Extraintestinal manifestation (EIM) of inflammatory bowel disease (IBD) is approximately 36%. Of genitourinary complications as an EIM of Crohn’s disease (CD), nephrolithiasis is the most common urinary complication in patients with CD. CD patients have been shown to have decreased urinary volume, pH, magnesium, and excretion of citrate, all of which are significant risk factors for nephrolithiasis. Genitourinary complications often occur in case of a severe longstanding disease and are associated with, the activity of bowel disease, especially in those who have undergone bowel surgery. As uncontrolled nephrolithiasis could impair renal function as well as adversely affect quality of life, proper monitoring, early detection, and prevention of the occurrence of urologic complications in CD is crucial. Few data are available about urolithiasis in patients with CD. Herein we report a case of a successful removal of a 2.7 cm calcium oxalate stone using percutaneous nephrolithotomy from a patient with long-standing CD with a previous surgery for small intestinal and colonic stricture.&lt;/p&gt;

Risk factors for urolithiasis

Risk factors for urolithiasis Abstract. The prevalence and incidence of kidney stones has continuously increased over the last years. Recent evidence suggests that kidney stones have a substantial morbidity including chronic kidney disease and end stage kidney disease as well as significantly increased risk for cardiovascular diseases. Thus, risk stratification - especially of high-risk patients - is mandatory in the management of kidney stone patients. There is a huge variety in risk factors for nephrolithiasis including general factors (such as young age at manifestation, familial disposition), genetic or acquired diseases with risk of stone formation, drugs etc. Several prediction scores have been developed to assess recurrence risk in kidney stone formers. However, only very few studies have investigated these tools and more evidence is needed in future to proof if these scores reliably predict stone recurrence risk.